26 results about "Sirtuin" patented technology

The present invention relates to compositions comprising NAD and, in some preferred embodiments, further comprising a CD38 inhibitor, an antioxidant, an endogenous cellular health molecule and / or a sirtuin activator as adjuncts. The present invention also relates to pharmaceutical compositions, dosage forms and methods for NAD delivery and supplementation.

The application discloses a SIRT protein promoter and application thereof, and belongs to the technical field of cosmetics, and particularly relates to a SIRT protein promoter; the active ingredient of the SIRT protein promoter is oligopeptide-6; the oligopeptide-6 can not only activate an AMPK signal path, up-regulate NAMPT gene expression, and improve intracellular NAD + level, thereby activating SIRT protein in dependence on NAD + ; and can effectively promote collagen production, and realize the effects of anti-wrinkle and skin tightening.

Provided is a novel use of a composition that contains S-1-propenyl cysteine and / or a salt thereof.　The present invention can be an eNAMPT increasing agent in which S-1-propenyl cysteine or a salt thereof is an active ingredient. The present invention can be an eNAMPT increasing agent that contains S-1-propenyl cysteine or a salt thereof and that is administered to an animal. Particularly, it is preferable that the present invention be used for increasing eNAMPT in blood.

The invention discloses a targeted multi-channel synergistic anti-aging composition as well as a preparation method and application thereof, and belongs to the technical field of functional foods and biological medicines. According to the composition disclosed by the invention, ginsenoside, a hawthorn polyphenol-chitosan phospholipid complex and spina date seed total saponins are taken as core active ingredients, and a specific Senlytics active ingredient and a natural mTOR inhibitor are compounded, so that the synergistic regulation of five anti-aging pathways, namely Sirtuins activation, mTOR inhibition, mitochondrial autophagy activation, CD38 inhibition and senescent cell removal, can be realized at the same time. The composition is natural in raw material source, high in safety and good in stability, can be prepared into various dosage forms such as capsules, solid beverages and oral liquid, is suitable for daily anti-aging and sub-health conditioning, and has wide application prospects in the fields of anti-aging health foods and biological medicines.

The invention discloses paeoniflorin serving as an SIRT1 agonist and application of the paeoniflorin. Test results prove that paeoniflorin can be stably combined with SIRT1 at an agonist site so as to promote the activity of deacetylase SIRT1. The deacetylase SIRT1 agonist disclosed by the invention has a good activation effect on a deacetylation reaction of SIRT1 and a p53 substrate on a molecular level. The application proves that paeoniflorin can significantly improve nano-zinc oxide-induced mouse kidney injury in vivo, and can be used as a potential medicine for treating nano-zinc oxide-induced kidney injury by improving renal dysfunction, activating kidney SIRT1 and increasing antioxidant enzyme activity. The new function of paeoniflorin found in the invention provides a new strategy for research and development of SIRT1 agonist drugs, and provides a new direction for development of nano-zinc oxide protective agents.

The present invention provides an aptamer for Sirtuin 2 and its application. The nucleotide sequence of the aptamer is shown in SEQ ID NO. 1, which solves the technical problems of poor stability and high cost of current antibodies that recognize Sirtuin 2.

The present invention relates to the pharmaceutical use of a combination of an SP / KLF transcription factor inhibitor, phorboxazole or a variant thereof, and a sirtuin inhibitor. The present invention provides the use of a sirtuin inhibitor and phorboxazole or a variant thereof for the manufacture of a medicament for the prevention and / or treatment of glioma. The present invention also provides a pharmaceutical composition for the prevention and / or treatment of glioma, comprising a sirtuin inhibitor and phorboxazole or a variant thereof, and optionally a pharmaceutically acceptable adjuvant. The glioma is adult glioma or pediatric glioma. The inventors of the present invention have found that the combination of a sirtuin inhibitor and phorboxazole or a variant thereof can significantly improve the therapeutic effect on glioma and reduce the side effects of single treatment.

The present invention relates to variants of sirtuin 6 for use in the treatment of non-alcoholic fatty liver disease.

This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having a 2-hydroxybenzoic acid structure which function as sirtuin (e.g., SIRT1, SIRT2, SIRT3, SIRT4, SIRT5, SIRT6, SIRT7) inhibitors and / or degraders which function as effective therapeutic agents for treating, ameliorating, and preventing disorders associated with sirtuin activity (e.g., melanoma, Ewing sarcoma, malignant peripheral nerve sheath tumor, non-small cell lung cancer). In addition, this invention also relates to a new class of proteolysis-targeting chimeras (PROTACs) (as defined herein) which function as sirtuin inhibitors and / or degraders within cancer and / or immune cells. Pharmaceutical compositions comprising said compounds are also within the scope of the present invention.

The present invention provides workflows for the discovery of nonallosteric sirtuin activation compounds. Workflows enable drug discovery of novel sirtuin activating compounds with prescribed effects on the binding in pockets near the active site interacting with flexible protein degrees of freedom around the active site. Novel kinetic models are used to confirm hit compounds and to improve their properties.

Provided is a novel use of a composition that contains S-1-propenylcysteine and / or a salt thereof.The present invention can be an eNAMPT increasing agent in which S-1-propenylcysteine or a salt thereof is an active ingredient. The present invention can be an eNAMPT increasing agent that contains S-1-propenylcysteine or a salt thereof and that is administered to an animal. Particularly, it is preferable that the present invention be used for increasing eNAMPT in blood.

The invention discloses a composition for delaying senescence and keeping skin young, the composition comprises three active components of PQQ, ergothioneine and NAD +, the mass ratio of PQQ to ergothioneine to NAD + is 1: 1: 1, the PQQ is used for protecting mitochondrial functions and promoting generation of new mitochondria; according to the ergothioneine, telomere shortening is delayed through an OCTN1 transporter mediated cell penetration mechanism; nAD + is used for activating a Sirtuins protein family and repairing DNA damage, the invention relates to the technical field of medicine, PQQ is delivered in a targeted manner through lipid nanoparticles, accurately acts on mitochondria, resists attack of 95% or more of free radicals, promotes generation of new mitochondria and delays cell aging from an energy source, high-purity ergothioneine penetrates through a cell membrane through OCTN1 transporter protein, and the effect of repairing DNA damage is achieved. The NAD < + > directly activates Sirtuins family proteins, the DNA damage repairing efficiency is improved by 60%, the skin collagen density and myocardial cell viability are remarkably improved, and physiological age signs are reversed.

The present invention relates to variants of sirtuin 6 for the treatment of non-alcoholic fatty liver disease.

This invention relates to a benzothiazole or benzimidazole derivative, a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the derivative as an active ingredient for the prevention or treatment of diseases related to the Silent Information Modulator (SIRTUIN) 7 protein, which exhibits excellent inhibitory activity against the SIRTUIN 7 protein and can be used for the prevention or treatment of diseases related to the SIRTUIN 7 protein.

Disclosed is a multi-functional nanoparticle delivery system comprising a biodegradable core of poly(lactic-co-glycolic acid) (PLGA) or calcium phosphate (CaP), encapsulating a nicotinamide adenine dinucleotide (NAD+) precursor and a sirtuin activator. Surrounding the core is a liposomal or polymeric layer containing one or more senolytic agents, and an outer layer of magnetic iron oxide nanoparticles for targeted delivery, external manipulation, and imaging. In some embodiments, the nanoparticle surface is functionalized for conjugation with autologous mesenchymal stem cells to enhance homing and regenerative potential. The system is pH-responsive, releasing its payload in acidic microenvironments typical of senescent or diseased cells, while remaining stable at physiological pH. This integrated design supports NAD+ restoration, sirtuin activation, senescent cell clearance, and tissue regeneration. Applications include treatment of age-related diseases, regenerative medicine, cardiovascular and neurodegenerative disorders, and cosmetic skin rejuvenation.

To provide a novel sirtuin 3 activator.SOLUTION: A sirtuin 3 activator comprising effusol and / or dehydroeffusol.SELECTED DRAWING: None

The invention relates to the technical field of animal experiment models, and discloses a feed composition capable of prolonging the life of mice and delaying senescence and application, and the feed composition is prepared by the following steps: raw material pretreatment: corn flour, soybean meal and wheat bran are respectively crushed and sieved by a 80-100 mesh sieve, and fish meal is subjected to ultraviolet sterilization treatment for 10-20 min; additive premixing: metformin and a carrier are mixed and ground, the carrier is microcrystalline cellulose or corn starch, and the mass ratio of metformin to the carrier is (1: 50)-(1: 100); and gradient mixing. Metformin in the feed composition activates an AMPK signal channel, enhances the cell energy perception ability, promotes a metabolic mode to be converted to mitochondrial oxidative phosphorylation direction and reduces glycolysis dependence, meanwhile, NAD + precursor substances in the synergistic components promote biosynthesis of nicotinamide adenine dinucleotide and drive the activity of SIRT deacetylase to be continuously improved, and the effect of improving the activity of the SIRT deacetylase is achieved. The cell metabolism homeostasis is jointly reconstructed, and the decline of senescence-related pathways is delayed from the molecular level.

The present application relates to a benzothiazole or benzimidazole derivative, a pharmaceutically acceptable salt thereof, and a pharmaceutical composition for preventing or treating a SIRTUIN 7 protein-related disease, which comprises the same as an active ingredient, and the SIRTUIN 7 protein has excellent inhibitory activity and can be used for preventing or treating a SIRTUIN 7 protein-related disease.

To find new applications for ceramide compositions. [Solution] A composition for activating sirtuin genes, comprising a ceramide composition, The ceramide composition is at least one bio-extracted ceramide composition selected from the group consisting of soy sauce lees extract ceramide composition, koji mold extract ceramide composition, and chicken foot extract ceramide composition. composition.

The present invention relates to a pharmaceutical composition for preventing or treating thyroid cancer, the composition comprising a substance that increases the level of the SIRT4 (sirtuin 4) gene or mRNA, or the level or activity of the SIRT4 protein.

Embodiments of the present disclosure pertain to methods of constructing a phage display library where at least 90% of combinatorial regions in the phage display library include at least one inframe amber codon. Further embodiments of the present disclosure pertain to the formed phage display libraries. Additional embodiments of the present disclosure pertain to methods of selecting peptides or proteins that bind to a desired target (e.g., a ligand binding site of a desired target) by utilizing the phage display libraries of the present disclosure. Further embodiments of the present disclosure pertain to peptides that have been screened from the phage display libraries and methods of the present disclosure, such as inhibitors of sirtuin 2, or inhibitors of ENL.

Provided is a novel use of a composition that contains a prescribed sulfur-containing compound, a salt thereof, or both.The present invention is a sirtuin activator or expression enhancer, a NAD+ increasing agent, or a senescent cell inhibitor containing, as an active ingredient, a compound (excluding S-1-propenylcysteine) represented by general formula 1A or 1B, or a salt thereof.

The present invention relates to variants of sirtuin 6 for the treatment of muscular diseases, in particular frailty syndrome and sarcopenia.

The present application relates to an anti-aging composition for improving cardiovascular function and a preparation method and application thereof, and the composition comprises L-ergothioneine, honokiol, quercetin and coenzyme Q10. The present application creatively designs an anti-aging composition for improving cardiovascular aging, which improves cardiovascular aging from four dimensions of "myocardial energy supply + anti-hypertrophy + endothelial protection + anti-oxidation". Coenzyme Q10 can restore myocardial mitochondrial ATP production, honokiol can reverse myocardial hypertrophy through NAD+ deacetylase, quercetin can improve endothelial function and reduce blood pressure, and L-ergothioneine can protect vascular endothelial cells from oxidative damage and inhibit the formation of ox-LDL. Through research, it is found that the four can cooperate and synergize with each other, and can jointly play an excellent role in improving cardiovascular aging, and achieve multiple protection for cardiovascular aging.

The invention discloses an application of SIRT1 activator dihydromyricetin in preparation of a medicine for treating acute liver injury. It is proved for the first time that dihydromyricetin serves as an effective liver protective agent, and acute liver injury is relieved through an unknown acetylation-dependent mechanism. DMY mitigates ALI by mitigating oxidative stress and inhibiting inflammatory response. In mechanism, DMY recovers expression of deacetylase SIRT1 in liver macrophages, SIRT1 and PRDX1 directly interact with each other, and deacetylation is carried out on the PRDX1 at a lysine 35 site. This deacetylation event reactivates the antioxidant function of PRDX1, inhibits the generation of proinflammatory cytokines, and inhibits polarization of M1 type macrophages, thereby remodeling the inflammatory microenvironment during ALI. The protection effect of DMY is reproduced through gene recovery SIRT1, and an SIRT1-PRDX1 shaft is determined as a core mediating factor of the SIRT1-PRDX1 shaft.

Provided is a novel use of a composition that contains S-1-propenylcysteine and / or a salt thereof. The present invention can be an eNAMPT increasing agent in which S-1-propenylcysteine or a salt thereof is an active ingredient. The present invention can be an eNAMPT increasing agent that contains S-1-propenylcysteine or a salt thereof and that is administered to an animal. Particularly, it is preferable that the present invention be used for increasing eNAMPT in blood.